Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy

Nienke M van de Velde, Melissa T Hooijmans, Aashley S D Sardjoe Mishre, Kevin R Keene, Zaïda Koeks, Thom T J Veeger, Iris Alleman, Erik W van Zwet, Jan-Willem M Beenakker, Jan J G M Verschuuren, Hermien E Kan, Erik H Niks, Nienke M van de Velde, Melissa T Hooijmans, Aashley S D Sardjoe Mishre, Kevin R Keene, Zaïda Koeks, Thom T J Veeger, Iris Alleman, Erik W van Zwet, Jan-Willem M Beenakker, Jan J G M Verschuuren, Hermien E Kan, Erik H Niks

Abstract

Objective: To identify the best quantitative fat-water MRI biomarker for disease progression of leg muscles in Becker muscular dystrophy (BMD) by applying a stepwise approach based on standardized response mean (SRM) over 24 months, correlations with baseline ambulatory tests, and reproducibility.

Methods: Dixon fat-water imaging was performed at baseline (n = 24) and 24 months (n = 20). Fat fractions (FF) were calculated for 3 center slices and the whole muscles for 19 muscles and 6 muscle groups. Contractile cross-sectional area (cCSA) was obtained from the center slice. Functional assessments included knee extension and flexion force and 3 ambulatory tests (North Star Ambulatory Assessment [NSAA], 10-meter run, 6-minute walking test). MRI measures were selected using SRM (≥0.8) and correlation with all ambulatory tests (ρ ≤ -0.8). Measures were evaluated based on intraclass correlation coefficient (ICC) and SD of the difference. Sample sizes were calculated assuming 50% reduction in disease progression over 24 months in a clinical trial with 1:1 randomization.

Results: Median whole muscle FF increased between 0.2% and 2.6% without consistent cCSA changes. High SRMs and strong functional correlations were found for 8 FF but no cCSA measures. All measures showed excellent ICC (≥0.999) and similar SD of the interrater difference. Whole thigh 3 center slices FF was the best biomarker (SRM 1.04, correlations ρ ≤ -0.81, ICC 1.00, SD 0.23%, sample size 59) based on low SD and acquisition and analysis time.

Conclusion: In BMD, median FF of all muscles increased over 24 months. Whole thigh 3 center slices FF reduced the sample size by approximately 40% compared to NSAA.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Heterogenous Fat Distribution in Vastus…
Figure 1. Heterogenous Fat Distribution in Vastus Lateralis (VL) and Semitendinosus (ST)
Example of regions of interest (B) and of heterogenous fat distribution from distal (A) to proximal (C) in the VL (A–D) and ST (A–C, E). (B) An example of heterogenous fat distribution in the axial plane of the quadriceps. To enhance visualization of the fat differences along the proximodistal axis of the muscles, patients are grouped according to their weighted fat of the whole muscle (light gray: 65% fat). The muscles are aligned based on the insertion of the biceps femoris short head (BFS) (marked as “center”) in D and E. Distal and proximal muscle parts are depicted in the left and right part of the figure, respectively. Blue lines: healthy controls; black/grey lines: Becker muscular dystrophy patients. Each line represents one individual participant. AL = adductor longus; AM = adductor magnus; BFL = biceps femoris long head; GR = gracilis; RF = rectus femoris; SM = semimembranosus; SR = sartorius; VI = vastus intermedius; VM = vastus medialis.
Figure 2. Flowchart of the Stepwise Process…
Figure 2. Flowchart of the Stepwise Process for Selection of MRI Measures
*Correlation with baseline North Star Ambulatory Assessment, 10-meter run test, and 6-minute walk test. 3C slices = 3 center slices; cCSA = contractile cross-sectional area; FF = fat fraction; SRM = standardized response mean; WM = whole muscle.
Figure 3. Mean Change in Fat in…
Figure 3. Mean Change in Fat in Thigh and Lower Leg Whole Muscles per Patient
Each patient is represented by a black and gray bar stitched together. Black and gray bars indicate mean change over thigh and lower leg muscles, respectively. Patients are subdivided in 4 groups based on their average weighted fat over all thigh and lower leg muscles (60% fat). *Mean change of zero.
Figure 4. Change in Fat and Contractile…
Figure 4. Change in Fat and Contractile Cross-Sectional Area (cCSA) Over 24 Months
(A) Change in fat over 24 months. (B) Change in cCSA over 24 months. Boxes show median (IQR). The lines represent the 10th–90th percentile with diamonds indicating values outside this window. Median baseline values are given at the left border. AL = adductor longus; AM = adductor magnus; BFL = biceps femoris long head; BFS = biceps femoris short head; EDL = extensor digitorum longus; GL = gastrocnemius lateralis; GM = gastrocnemius medialis; GR = gracilis; PR = peroneus; RF = rectus femoris; SM = semimembranosus; SOL = soleus; SR = sartorius; ST = semitendinosus; TA = tibialis anterior; TP = tibialis posterior; VI = vastus intermedius; VL = vastus lateralis; VM = vastus medialis.
Figure 5. Relation Between Change in Function…
Figure 5. Relation Between Change in Function Tests and Fat Fraction (FF)
Change in whole thigh FF of 3 center slices vs (A) North Star Ambulatory Assessment (NSAA) and (B) 10-meter run test (TMR) velocity. Closed arrows: patients with baseline and follow-up measurements. Open triangles: patients with only 1 measurement (baseline). Horizontal arrows indicate functionally stable patients but with a change in FF.

References

    1. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy: I: natural history. J Neurol. 1993;240(2):98-104.
    1. Comi GP, Prelle A, Bresolin N, et al. . Clinical variability in Becker muscular dystrophy: genetic, biochemical and immunohistochemical correlates. Brain. 1994;117(pt 1):1-14.
    1. Burakiewicz J, Sinclair CDJ, Fischer D, Walter GA, Kan HE, Hollingsworth KG. Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy. J Neurol. 2017;264(10):2053-2067.
    1. Straub V, Balabanov P, Bushby K, et al. . Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 2016;15(8):882-890.
    1. Willcocks RJ, Rooney WD, Triplett WT, et al. . Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort. Ann Neurol. 2016;79(4):535-547.
    1. Fischmann A, Hafner P, Fasler S, et al. . Quantitative MRI can detect subclinical disease progression in muscular dystrophy. J Neurol. 2012;259(8):1648-1654.
    1. Barnard AM, Willcocks RJ, Triplett WT, et al. . MR biomarkers predict clinical function in Duchenne muscular dystrophy. Neurology. 2020;94(9):e897-e909.
    1. Naarding KJ, Reyngoudt H, van Zwet EW, et al. . MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy. Neurology. 2020;94(13):e1386-e1394.
    1. Nagy S, Schadelin S, Hafner P, et al. . Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy. Muscle Nerve. 2020;61(1):63-68.
    1. Bonati U, Hafner P, Schadelin S, et al. . Quantitative muscle MRI: a powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Disord. 2015;25(9):679-685.
    1. Morrow JM, Sinclair CD, Fischmann A, et al. . MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 2016;15(1):65-77.
    1. Murphy AP, Morrow J, Dahlqvist JR, et al. . Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial endpoints. Ann Clin Transl Neurol. 2019;6(6):1033-1045.
    1. Gidaro T, Reyngoudt H, Le Louer J, et al. . Quantitative nuclear magnetic resonance imaging detects subclinical changes over 1 year in skeletal muscle of GNE myopathy. J Neurol. 2020;267(1):228-238.
    1. Sheikh AM, Rudolf K, Witting N, Vissing J. Quantitative muscle MRI as outcome measure in patients with Becker muscular dystrophy: a 1-year follow-up study. Front Neurol. 2020;11:613489.
    1. Fischer D, Hafner P, Rubino D, et al. . The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: a cross-sectional study. Neuromuscul Disord. 2016;26(7):414-422.
    1. Barp A, Bello L, Caumo L, et al. . Muscle MRI and functional outcome measures in Becker muscular dystrophy. Sci Rep. 2017;7(1):16060.
    1. Maggi L, Moscatelli M, Frangiamore R, et al. . Quantitative muscle MRI protocol as possible biomarker in Becker muscular dystrophy. Clin Neuroradiol. 2021;31(1):257-266.
    1. Tasca G, Iannaccone E, Monforte M, et al. . Muscle MRI in Becker muscular dystrophy. Neuromuscul Disord. 2012;22(suppl 2):S100-S106.
    1. van den Bergen JC, Ginjaar HB, van Essen AJ, et al. . Forty-five years of Duchenne muscular dystrophy in the Netherlands. J Neuromuscul Dis. 2014;1(1):99-109.
    1. McDonald CM, Henricson EK, Han JJ, et al. . The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500-510.
    1. Mazzone E, Martinelli D, Berardinelli A, et al. . North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20(11):712-716.
    1. Wokke BH, van den Bergen JC, Versluis MJ, et al. . Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul Disord. 2014;24(5):409-416.
    1. Hooijmans MT, Froeling M, Koeks Z, et al. . Multi-parametric MR in Becker muscular dystrophy patients. NMR Biomed. 2020:e4385.
    1. Akima H, Lott D, Senesac C, et al. . Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2012;22(1):16-25.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Erlbaum Associates; 1988.
    1. The Natural History Study of Becker Muscular Dystrophy [NL50171.50058.50114].
    1. Willis TA, Hollingsworth KG, Coombs A, et al. . Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One. 2013;8(8):e70993.
    1. Andersen G, Dahlqvist JR, Vissing CR, Heje K, Thomsen C, Vissing J. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J Neurol. 2017;264(3):438-447.
    1. Nunez-Peralta C, Alonso-Perez J, Llauger J, et al. . Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles. J Cachexia Sarcopenia Muscle. 2020;11(4):1032-1046.
    1. Heskamp L, van Nimwegen M, Ploegmakers MJ, et al. . Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI. Neurology. 2019;92(24):e2803-e2814.
    1. Mul K, Vincenten SCC, Voermans NC, et al. . Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neurology. 2017;89(20):2057-2065.
    1. Reyngoudt H, Marty B, Boisserie JM, et al. . Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. Eur Radiol. Epub 2020 Nov 21.
    1. Hooijmans MT, Niks EH, Burakiewicz J, et al. . Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy. Neuromuscul Disord. 2017;27(5):458-464.
    1. Chrzanowski SM, Baligand C, Willcocks RJ, et al. . Multi-slice MRI reveals heterogeneity in disease distribution along the length of muscle in Duchenne muscular dystrophy. Acta Myol. 2017;36(3):151-162.
    1. Janssen BH, Voet NB, Nabuurs CI, et al. . Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS One. 2014;9(1):e85416.
    1. Schlaffke L, Rehmann R, Rohm M, et al. . Multi-center evaluation of stability and reproducibility of quantitative MRI measures in healthy calf muscles. NMR Biomed. 2019;32(9):e4119.
    1. Forbes SC, Walter GA, Rooney WD, et al. . Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology. 2013;269(1):198-207.
    1. Hu HH, Yokoo T, Bashir MR, et al. . Linearity and bias of proton density fat fraction as a quantitative imaging biomarker: a multicenter, multiplatform, multivendor phantom study. Radiology. 2021;298(3):640-651.
    1. Kugathasan U, Evans MRB, Morrow JM, et al. . Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in hereditary sensory neuropathy type 1. J Neurol Neurosurg Psychiatry. 2019;90(8):895-906.
    1. Willcocks RJ, Arpan IA, Forbes SC, et al. . Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord. 2014;24(5):393-401.
    1. Hooijmans MT, Niks EH, Burakiewicz J, Verschuuren JJ, Webb AG, Kan HE. Elevated phosphodiester and T2 levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients. NMR Biomed. 2017;30(1).

Source: PubMed

3
Abonner